B2B SaaS Provider · vs · Data Provider / Broker
CGI vs Deluxe
Structured technology and market comparison · 2026
Direct Feature Comparison
CGI · vs · DeluxeEnterprise consulting and vertical software provider for regulated industries.
B2B provider of payments, receivables, marketing data and brand operations.
Analyze all overlapping signals and tech stacks for CGI and Deluxe
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between CGI and Deluxe?
When comparing CGI and Deluxe, both platforms operate within the Measurement & Analytics Platform and Payment Gateway & Orchestration ecosystem. CGI is positioned as Enterprise consulting and vertical software provider for regulated industries, whereas Deluxe focuses on B2B provider of payments, receivables, marketing data and brand operations. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to CGI and Deluxe?
When evaluating CGI and Deluxe, enterprise buyers also consider other platforms in Measurement & Analytics Platform and Payment Gateway & Orchestration. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of CGI and Deluxe compare?
CGI is headquartered in Canada (founded in 1976) with >5,000 employees. Deluxe is based in United States (founded in 1915) with 1,001–5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: CGI vs Deluxe
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
CGI
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for CGI (2026-11-03)
On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.
- Corcept Therapeutics furnished its Q3 2026 financial results for the period ended September 30, 2026, via an 8-K press release notice on November 3, 2026.
- The disclosure was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Exhibit 99.1 containing the full press release.
- The filing was formally signed and authorized by Chief Financial Officer Atabak Mokari on November 3, 2026.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for CGI (2026-11-03)
Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.
- Q3 2026 net product revenue grew 64.0% year-over-year to $340.47M, with newly approved oncology drug Lifyorli contributing $91.41M and hypercortisolism products generating $249.07M.
- Operating income for the quarter reached $114.72M compared to $10.22M in Q3 2025, while diluted earnings per common share expanded to $1.01 compared to $0.16.
- The resubmitted New Drug Application (NDA) for relacorilant in endogenous hypercortisolism has an assigned PDUFA target action date of December 17, 2026.
- ·CGI
CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems
CGI has been named a Leader in the 2026 IDC MarketScape Worldwide Trade Finance Systems Vendor Assessment. The report highlights CGI Trade360, which supports operations in 98 countries and 348 bank locations with more than 247,000 corporate portal users. CGI Trade360 recently celebrated its 25th anniversary and processes over 15.5 million transactions annually. The recognition reflects CGI's investment in trade finance technology, AI integration, and client collaboration.
- On September 30, 2026, CGI announced it was named a Leader in the 2026 IDC MarketScape Worldwide Trade Finance Systems Vendor Assessment.
- CGI Trade360 supports operations in 98 countries and 348 bank locations, serving more than 247,000 corporate portal users.
- CGI Trade360 recently celebrated its 25th anniversary and processes more than 15.5 million transactions annually.
Deluxe
Recent Signals
No recent market signals documented for Deluxe in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners CGI and Deluxe share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks